Current and Potential Use of Pathological Targets in the Treatment of Hodgkin Lymphoma

American Journal of Hematology - United States
doi 10.1002/ajh.25054
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

Klinicka Onkologie
Oncology
2016English

Current Considerations in AYA Hodgkin Lymphoma

British Journal of Haematology
Hematology
2018English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2012English

Treatment of Relapse and Refractory Hodgkin Lymphoma

Oncogematologiya
OncologyHematology
2017English

On the Prediction of Hodgkin Lymphoma Treatment Response

Clinical and Translational Oncology
MedicineCancer ResearchOncology
2015English

Clinico-Pathological Significance of Immunohistochemically Marked Tumor-Associated Macrophage in Classic Hodgkin Lymphoma

Journal of the Egyptian National Cancer Institute
2020English

Sphingolipids in Inflammation: Pathological Implications and Potential Therapeutic Targets

British Journal of Pharmacology
Pharmacology
2009English

Treatment of Early Stages Hodgkin Lymphoma During Pregnancy

Mediterranean Journal of Hematology and Infectious Diseases
Infectious DiseasesHematology
2018English

Pesticide Product Use and Risk of Non-Hodgkin Lymphoma in Women

Environmental Health Perspectives
MutagenesisPublic HealthEnvironmentalHealthToxicologyOccupational Health
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy